An RNA Therapy for Muscle Loss on GLP-1s

A study published in the Proceedings of the National Academy of Sciences on 6 October 2026 describes an experimental RNA-based therapy that helped mice keep more lean muscle while losing weight on semaglutide^[1]. The therapy has been tested in mice only. It is not approved, not for sale, and has not been given to a single human patient. What follows is what the mouse data showed, and why the problem it targets, losing muscle while losing weight on a GLP-1 drug, is already documented in people.

What the mice received

The therapy targets a gene called ZFP423, which normally acts as a brake on white fat's ability to convert into beige fat (a type of fat tissue that burns calories as heat rather than storing them)^[1]. Researchers at Northwestern University, working with Duke University, the University of Michigan and the drug-development company Ionis Pharmaceuticals, built a short, lab-made strand of genetic material called an antisense oligonucleotide (a molecule that blocks a single gene's instructions without altering the gene itself) to switch ZFP423 off in fat tissue^[3]. In lean mice and in mice fed a high-fat diet to induce obesity, weekly treatment with the antisense oligonucleotide raised body temperature and oxygen use and improved blood sugar control, lipid handling and insulin sensitivity^[1].

Paired with semaglutide, mice lost less muscle

The researchers then combined the antisense treatment with semaglutide, the GLP-1 receptor agonist sold as Wegovy and Ozempic. Mice on the combination lost more weight and more fat than mice on semaglutide alone, while losing less lean mass: about 5.5% of lean mass on the combination, against roughly 10% on semaglutide by itself^[3]. Final body-fat measurements ran to about 4 grams on the combination versus close to 8 grams on semaglutide alone^[3]. The combination also improved glucose tolerance and lowered liver triglycerides compared with semaglutide on its own^[1].

Joseph Bass, who directs the Center for Diabetes and Metabolism at Northwestern University Feinberg School of Medicine and co-led the work, described the finding this way: the team had identified 'an RNA therapy that promotes thermogenesis and, when combined with the GLP-1 drug semaglutide, helps preserve lean muscle mass'^[3].

Lean-mass loss on GLP-1s is a documented finding

The problem this therapy is aimed at is not hypothetical. In an exploratory body-composition analysis of the STEP 1 trial that used DXA scans on a subset of participants, total lean body mass fell by 9.7% at 68 weeks in people taking semaglutide 2.4 mg, alongside a 19.3% drop in fat mass and a 27.4% drop in visceral fat^[2]. Because fat fell by so much more than muscle, the share of body weight made up of lean tissue actually rose over the same period. But the absolute loss of lean tissue was real, and it is the reason researchers and clinicians managing patients on semaglutide and tirzepatide keep raising the question of how to protect muscle during rapid weight loss^[2].

Our semaglutide reference page lists this as an open question the STEP programme raised years ago and nobody has closed since.

What we don't yet know

This is mouse data. No antisense therapy targeting ZFP423 has been tested in a person, and Northwestern's own account of the work says the team is now testing similar RNA therapies in human cells, an early laboratory step that sits well before any human trial^[3]. Rodent thermogenic-fat responses have historically translated unevenly to humans, so a strong mouse result here does not predict a strong human result. Northwestern has filed a provisional patent covering the ZFP423-targeting method, which signals commercial interest rather than clinical proof^[3]. There is no public timeline for a human trial, no published safety data in mice beyond the metabolic measures reported here, and no indication yet of how such a therapy would be delivered or dosed if it ever reached patients.

What this means if you are on a GLP-1 now

Nothing about this study changes what is available today. If you are taking semaglutide or another GLP-1 receptor agonist and are concerned about muscle loss, that is a conversation for your prescribing clinician, not a reason to look for an unapproved RNA product online. Clinicians managing patients on these drugs already discuss strategies such as resistance training and adequate protein intake as open topics in the muscle-preservation conversation, and none of that depends on a mouse-stage therapy that may or may not ever reach the clinic. Whether an RNA-based add-on like this one eventually becomes part of that conversation is a question for future human trials to answer, not a promise this paper makes.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.